BioSight has received approval from the US Food and Drug Administration (FDA) and the Israeli Ministry of Health to begin a Phase llb clinical trial of BST-236 to treat Acute Myeloid Leukaemia (AML).

Expected to commence in the upcoming month, the trial will be carried out in 25 medical centres in the US and Israel.

As part of the trial, BST-236 will be provided as a single agent treatment for newly diagnosed AML patients, either de novo or secondary to myelodysplastic disorder (MDS) who are unfit for standard chemotherapy due to its severe toxicity.

This patient population is estimated to represent a third to half of the AML patients.

BioSight CEO Dr Ruth Ben Yakar said: “The encouraging results of the Phase l/ll study suggest that BST-236 may serve as an improved treatment option compared to the approved drugs available today for this population, including for patients aged 75 or older.

“We think it is very important to approach these patients, mainly due to the general increase in the population’s age and quality of life.”

“We think it is very important to approach these patients, mainly due to the general increase in the population’s age and quality of life, and we believe we can provide them with a safer and more effective treatment.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the Phase l/ll trial, BioSight enrolled 26 acute leukaemia patients to treat them with BST-236 as a single agent.

The trial primarily included older patients with poor prognosis baseline characteristics, including prior treatment with hypomethylating agents for MDS.

Results from the trial showed that BST-236 was safe and well tolerated at high doses, with no neurological or gastrointestinal toxicities or renal failure.

The upcoming Phase llb trial aims to achieve the same results as the Phase l/ll study, but in a larger number of patients in the US and Israel.